**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

Claims 1-4 (canceled)

Claim 5 (currently amended): A method of increasing the infectivity of a cell to a viral vector by treatment of the cell with a micro-calpain inhibitor , wherein said method is practiced ~~*in vitro* or~~ *ex vivo*, and wherein said method comprises selecting a cell whose infectivity is to be increased, and co-administrating said micro-calpain inhibitor and said viral vector to said cell.

Claim 6 (original): The method of claim 5 wherein said viral vector is an adenoviral vector.

Claim 7 (previously presented): The method of claim 6 wherein the micro-calpain inhibitor is calpain inhibitor 1.

Claims 8-20 (canceled)

Claim 21 (previously presented): The method of claim 6 wherein said adenoviral vector is replication deficient.

Claim 22 (currently amended): The method of claim 21 wherein said replication deficient adenoviral vector ~~encodes~~ comprises a therapeutic transgene.

Claim 23 (previously presented): The method of claim 22 where said transgene is selected from the group consisting of cytostatic genes and pro-apoptotic genes.

Claim 24 (previously presented): The method of claim 23 wherein the gene is a cytostatic gene.

Claim 25 (previously presented): The method of claim 24 wherein the gene is the p21 gene.

Claim 26 (previously presented): The method of claim 23 wherein the gene is a pro-apoptotic gene.

Claim 27 (previously presented): The method of claim 26 wherein the gene is p53.

Claim 28 (previously presented): The method of claim 5 wherein the vector is replication competent.

Claim 29 (previously presented): The method of claim 28 wherein the replication competent vector is a conditionally replicating viral vector.

Claim 30 (previously presented): The method of claim 29 wherein the conditionally replicating viral vector further comprises an expression cassette which expresses a pro-apoptotic gene.

Claim 31 (previously presented): The method of claim 30 wherein the pro-apoptotic gene is the E3-11.6K gene.

Claim 32 (canceled)

Claim 33 (previously presented): The method of claim 31 wherein the viral vector is a replication deficient adenoviral vector and the cell is a producer cell capable of complementing the deleted functions of the replication deficient adenoviral vector.

Claim 34 (previously presented): The method of claim 33 wherein the replication deficient adenoviral vector lacks a functional E1 region and the producer cell is a 293 cell.

Claim 35 (currently amended): The method of claim ~~32~~ 5 wherein said ~~*in vitro* practice of the~~ method is practiced in a process to purge tumor cells from a stem cell product by exposing said stem cell product to a calpain inhibitor prior to the administration of a viral vector.

Claim 36 (previously presented): The method of claim 35 wherein said viral vector is an adenoviral vector that encodes and expresses the p53 tumor suppressor gene.

Claim 37 (new): A method of infecting a human cell with a virus, comprising: contacting said cell *ex vivo* with an amount of a micro-calpain inhibitor sufficient to increase the infectivity of said cell to said virus; and co-administrating said virus to said cell.